GAD THOMAS (President and Chairman) sold 26.5% of their position (150K shares) of Y-MABS THERAPEUTICS, INC. on the open market
Open‑market sale worth $795.4K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 11/22/2023ACC: 0001104659-23-120804
DirectorOfficer· President and Chairman
Since Sep 2018
-150K
Net shares
Net seller
$795.4K
Total sold
2
Open market trades
0B · 2S
2
Total transactions
150K disposed
Non-Derivative Transactions2
Common Stock
Indirect
Shares
−75K
Price / share
$5.30
Trade value
$397.40K
% of position
13.3%
11/20/2023
565.03K→490.03K
Common Stock
Indirect
Shares
−75K
Price / share
$5.31
Trade value
$397.99K
% of position
15.3%
11/21/2023
490.03K→415.03K
Total
Net shares
−150K
Net value
-$795.38K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 11/20/2023 | S · Sale | −75K | $5.30 | $397.40K | 13.3% | 565.03K | 490.03K |
| Common Stock Indirect | 11/21/2023 | S · Sale | −75K | $5.31 | $397.99K | 15.3% | 490.03K | 415.03K |
| Total | −150K | -$795.38K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)2
Common Stock
IndirectShares owned60K
Common Stock
DirectShares owned90.50K
Total
90.50K direct·60K indirect150.50K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 60K | Indirect |
| Common Stock | 90.50K | Direct |
| Total | 150.50K | 90.50K direct·60K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported